• Sophie Anker, Katrin Hinderhofer, Julian Baur, Christian Haupt, Christoph Röcken, Jörg Beimler, Martin Zeier, Markus Weiler, Elke Wühl, Christoph Kimmich, Stefan Schönland, and Ute Hegenbart.
• Department of Internal Medicine V (Haematology, Oncology and Rheumatology), University Hospital Heidelberg, Heidelberg, Germany.
• Amyloid. 2022 Dec 1; 29 (4): 245254245-254.

AbstractLysozyme-derived (ALys) amyloidosis is a rare type of hereditary amyloidosis. Nine amyloidogenic variants and ∼30 affected families have been described worldwide. The most common manifestations are renal dysfunction, gastrointestinal tract symptoms, and sicca syndrome. We report on the clinical course of ten patients from six families representing one of the largest cohorts published so far. Seven patients carried the W64R variant showing the whole spectrum of ALys-associated symptoms. Two patients-a mother-son pair-carried a novel lysozyme variant, which was associated with nephropathy and peripheral polyneuropathy. In accordance with previous findings, the phenotype resembled within these families but did not correlate with the genotype. To gain insights into the effect of the variants at the molecular level, we analysed the structure of lysozyme and performed comparative computational predictions on aggregation propensity and conformational stability. Our study supports that decreased conformational stability is a key factor for lysozyme variants to be prone to aggregation. In summary, ALys amyloidosis is a very rare, but still heterogeneous disease that can manifest at an early age. Our newly identified lysozyme variant is associated with nephropathy and peripheral polyneuropathy. Further research is needed to understand its pathogenesis and to enable the development of new treatments.

13 keywords...

hide…